TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lexaria Bioscience ( (LEXX) ) has shared an update.
Lexaria Bioscience Corp. has engaged a global life science business development advisory firm to enhance its business development activities, supported by a recent $4 million equity financing. This strategic move aims to expand outreach in the pharmaceutical and biotechnology sectors, leveraging Lexaria’s DehydraTECH technology. Additionally, the company has been awarded four new patents, strengthening its intellectual property portfolio and supporting its R&D programs in fields such as diabetes, hypertension, and antiviral treatments.
The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, primarily focusing on the pharmaceutical industry. The company is known for its patented DehydraTECH technology, which is applied across various sectors including diabetes control, weight loss, hypertension, seizure disorders, antiviral applications, and hormone replacement.
Average Trading Volume: 552,250
Technical Sentiment Signal: Strong Sell
Current Market Cap: $18.6M
Find detailed analytics on LEXX stock on TipRanks’ Stock Analysis page.